Identification of ACE and HSPB8 as novel drug targets for LUSC treatment and prognosis based on a prognostic model integrating epigenetic regulation and endoplasmic reticulum stress-related genes

This comprehensive bioinformatics and experimental study highlights ACE and HSPB8 as novel targets for LUSC treatment and prognosis, emphasizing their roles in epigenetic regulation and ERS. The risk model demonstrates preliminary potential for guiding personalized therapeutic strategies, emphasizing the need for a deeper understanding of epigenetic mechanisms and ERS in cancer development and treatment. Thus, our findings open avenues for further research into targeted therapies for LUSC, aiming to improve patient outcomes through precision medicine that considers both epigenetic factors and ERS.